



Biotech Daily

Tuesday July 19, 2016

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: ADMEDUS UP 10%; NEUREN DOWN 11%**
- * **OVENTUS OPENS UP 20%, CLOSES UP 40%**
- * **MOBIUS TAKES 5% OF OVENTUS**
- * **2nd US PATENT FOR USCOM BP+**
- * **TBG CHINA PLANT EARNS FIRST HLA-TYPING REVENUE**
- * **MEDIVAC DEED OF COMPANY ARRANGEMENT APPROVED**
- * **PHYLOGICA LOSES CO-FOUNDER, CEO DR RICHARD HOPKINS**
- * **SOMNOMED DEREK SMITH CEO STARTS ON \$598k**

MARKET REPORT

The Australian stock market slipped 0.13 percent on Tuesday July 19, 2016 with the ASX200 down 7.2 points to 5,451.3 points.

Ten of the Biotech Daily Top 40 stocks were up, 19 fell, 10 traded unchanged and one was untraded. All three Big Caps were up.

Admedus was the best, up 3.5 cents or 10.1 percent to 38 cents with 505,785 shares traded.

Biotron and Impedimed climbed more than four percent; Atcor was up 3.7 percent; Factor Therapeutics, IDT and Resmed rose two percent or more; Actinogen and Nanosonics were up more than one percent; with Cochlear, CSL, Reva and Sirtex up by less than one percent.

Neuren led the falls, down 0.7 cents or 11.3 percent to 5.5 cents, with 1.5 million shares traded.

Antisense lost 8.6 percent; Orthocell fell 7.35 percent; Genetic Technologies shed five percent; Anteo and Opthea fell more than four percent; Mesoblast and Universal Biosensors were down more than three percent; Airxpanders and Prana shed two percent or more; Avita, Clinuvel, Compumedics, Ellex, Living Cell, Pharmaxis, Uscom and Viralytics were down more than one percent; with Starpharma down 0.7 percent.

OVENTUS MEDICAL

Oventus has raised \$12 million and opened on the ASX under the code OVN at 60 cents, a 20 percent premium to its initial public offer price of 50 cents.

Oventus said its initial public offer to commercialize the O2vent anti-snoring device was fully-underwritten by Bell Potter Securities (BD: Jun 8, 20, 2016).

Oventus chairman Dr Mel Bridges previously said that the O2vent sleep apnoea and snoring device would "turn the global sleep market on its head" and be cash-flow-even in two years.

Dr Bridges said that the mouth guard device was "a disruptive technology" and different from the array of competition in that it directed airflow to the back of the mouth and had intellectual property protection, which many other devices did not.

Oventus closed up 20 cents at 70 cents with 706,417 shares traded.

OVENTUS MEDICAL

Mobius Medical Investments says it has become a substantial shareholder in Oventus with 3,732,390 shares (5.18%).

The Sydney-based Mobius Medical Investments said it acquired the shares on September 23, 2015.

The substantial shareholder form was signed by Mobius founder and director Stefan Czyniewski, who is also a founder and director of contract research organization Mobius Medical.

Mr Czyniewski told Biotech Daily the two companies were separate entities.

USCOM

Uscom says it has been allowed a US patent covering the method and apparatus for producing central pressure waveforms in an oscillometric blood pressure system.

Uscom said that the US Patent and Trademarks Office had allowed the patent, entitled 'Method and apparatus for producing a central pressure waveform in an oscillometric blood pressure system' providing coverage until July 12, 2009.

The company said the patent covered the method and apparatus of its BP+ central blood pressure diagnostic and combined with the patent for the central pressure calculations to measure the blood pressure wave forms generated at the heart, would protect the BP+ device from competitors attempting to copy the technology (BD: Jul 11, 2016).

Uscom said the patented BP+ technologies "improve the measurement of blood pressure, a fundamental clinical measurement and represent some of the most advanced and innovative of cardiovascular technologies".

"The central pulse pressure wave measurements generated by the BP+ have application in the diagnosis and management of hypertension and heart failure and have only previously been available using cardiac catheters," Uscom said.

The company said that central blood pressure measurement was reimbursed in the US and the BP+ was being prepared for US release, expected to retail at \$US3,000, with competitors ranging as high as \$US20,000.

Uscom executive chairman Prof Rob Phillips said the patent was "further recognition of the strength and novelty of our Uscom BP+ suprasystolic oscillometric central blood pressure monitoring science".

Uscom fell half a cent or 1.6 percent to 30 cents.

TBG DIAGNOSTICS

TBG says it has begun earning revenue from human leukocyte antigen (HLA) genomic typing services at its Xiamen, China laboratory.

TBG said that the Xiamen facility was completed in mid-2015 and provided services across the human leukocyte antigen typing suite including Illumina's Miseq Next Generation Sequencing, TBG Morgan Typing kits for low-resolution HLA typing and kits for high-resolution HLA typing.

The company said that Xiamen was its second laboratory in Asia with the Taiwan laboratory accredited by the American Society for Histocompatibility and Immunogenetics and the Xiamen facility expected to gain Society accreditation.

TBG said the China facility was the result of two years of preparation and building on its in-vitro diagnostics-related nucleic acid testing kits and service, widening its scope to infectious diseases, oncology, blood screening and genetic testing.

The company said China was expected to be the fastest growing molecular diagnostics market with sales estimated at \$US3.5 billion by 2024.

TBG said that chief operating officer Eugene Cheng said the company was "pleased to announce ... that HLA typing has commenced in Xiamen and first revenues have been recorded at our world class facility".

"We anticipate further contracts with other clinics and customers in the coming months," Mr Cheng said.

TBG was unchanged at 18.5 cents.

MEDIVAC

Chartered accountants Hall Chadwick says that Medivac creditors have approved a deed of company arrangement (BD: Mr 1, 2016).

Hall Chadwick said that Richard Albarran, Brent Kijurina and Cameron Shaw were appointed Medivac administrators on April 22, 2015 and a creditors meeting on June 17, 2016 resolved to execute a deed of company arrangement and on July 15, 2016 the administrators executed the arrangement with Mr Albarran, Mr Kijurina and Mr Shaw appointed deed administrators.

Medivac was attempting to commercialize its Metamizer medical waste system and Sunnywipes hand hygiene products (BD: May 13, 2011; May 7, 2012).

In 2012, the company merged with Republica Capital and in 2014 sought funds to rebadge itself as Woolwich Capital (BD: Oct 29, 2012; Jan 31, 2014).

Last year, Medivac said it had a \$200,000 converting loan to re-list on the ASX, changed its board and was conducting a review of its business (BD: Aug 10, 2015).

PHYLOGICA

Phylogica says Dr Richard Hopkins resigned as a director from last night and will step-down as chief executive officer in October "to pursue other strategic interests".

Phylogica said that Dr Hopkins was appointed as chief executive officer in July, 2013 but had been with the company as a co-founding shareholder for 10 years.

Dr Hopkins and chair Stephanie Unwin said the decision "was mutual and amicable".

The company said that it had begun an international search for senior leadership role or roles to take it through its drug development phase to a preclinical trial.

Phylogica said the board, including Dr Doug Wilson, Jeremy Curnock Cook and shareholder Dr Bernard Hockings, would support Dr Paul Watt and the scientific team.

Phylogica was unchanged at 1.4 cents with 9.1 million shares traded.

SOMNOMED

Somnomed says Derek Smith has been appointed chief executive officer, with a base salary of \$US450,000 (\$A598,000) from September 1, 2016.

Somnomed said that executive chairman Dr Peter Neustadt would return to his role as non-executive chairman.

The company said that Mr Smith was previously an executive with the Murrysville, Pennsylvania-based Respironics Inc and had worked in sales and marketing at E Merck, Datex Ohmeda and McKesson.

Somnomed said that Mr Smith held a Bachelor of Science from Newcastle University, England and would be based in Denver, Colorado.

The company said that Mr Smith would have a base salary of \$US450,000 with a maximum bonus of \$US225,000 subject to key performance indicators and receive 900,000 options in three tranches from October 2016 to October 2018, exercisable at the 30-day volume-weighted average price to the date of issue.

Somnomed was unchanged at \$3.33.